)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
Anavex Life Sciences (AVXL) investor relations material
Anavex Life Sciences Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary25 Nov, 2025
Executive summary
Focused on advancing oral Blarcamesine and ANAVEX3-71 for neurodegenerative and neuropsychiatric diseases, with ongoing regulatory and clinical trial progress in Alzheimer's, Parkinson's, Rett syndrome, Fragile X, and schizophrenia.
Expectation of a negative CHMP opinion on Blarcamesine's MAA in Europe, with plans to request re-examination and present new biomarker and clinical data.
Expansion of strategic partnerships and corporate development activities, including presentations at major industry conferences.
Financial highlights
Cash and cash equivalents were $102.6 million at September 30, with a current balance exceeding $120 million and no debt, supporting a runway of more than three years.
Research and development expenses for the quarter were $7.3 million, down from $11.6 million year-over-year; general and administrative expenses were $3.5 million, up from $2.7 million.
Net loss for the quarter was $9.8 million, or $0.11 per share.
For the year ended September 30, 2025, net loss was $46.4 million ($0.54 per share), compared to $43.0 million ($0.52 per share) in the prior year.
Stockholders' equity at September 30, 2025, was $94.9 million, down from $120.3 million a year earlier.
Outlook and guidance
Immediate request for CHMP re-examination upon formal adoption of negative opinion, with a potential new decision in approximately four months.
Ongoing engagement with U.S. FDA and exploration of regulatory pathways in additional geographies.
Multiple regulatory and clinical trial updates expected for Blarcamesine and ANAVEX3-71 in 2026.
What specific biomarker data for blarcamesine EU reexam?
ANAVEX 3-71: Path to AD depression disease mod claims?
Update on blarcamesine strategic partnership efforts.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Anavex Life Sciences earnings date
43rd Annual J.P. Morgan Healthcare Conference15 Jan, 2026
Next Anavex Life Sciences earnings date
43rd Annual J.P. Morgan Healthcare Conference15 Jan, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. The company's lead drug candidate is 2-73 that has completed phase II clinical trial for the treatment of Alzheimer's disease. Its programs also includes ANAVEX 3-71, which is in pre-clinical testing for the treatment of amyotrophic lateral sclerosis disease; and ANAVEX 1-41, a pre-clinical stage small molecule compound for the treatment of epilepsy.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage